Retatrutide

Retatrutide is a single-peptide triple agonist targeting the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon (GCG) receptor simultaneously. This triple targeting sets it apart from earlier single- and dual-agonist weight-management peptides such as semaglutide (GLP-1 only) and tirzepatide (GIP/GLP-1).

The glucagon receptor activation is the key differentiator: while GLP-1 agonism suppresses appetite and GIP agonism enhances insulin secretion, glucagon agonism directly increases resting energy expenditure and hepatic lipid oxidation. In rodent and non-human primate models, this translated to greater fat-mass loss compared to GLP-1 monotherapy, even at equivalent caloric intake — suggesting a genuine metabolic-acceleration component beyond appetite suppression alone.

Binding affinity studies indicate that retatrutide's activity at the human GCG receptor is roughly balanced with its GLP-1 receptor potency, yielding a profile that simultaneously reduces energy intake and increases energy output. The ~6-day half-life (conferred by a fatty-acid side chain promoting albumin binding) supports once-weekly administration in research protocols.

Retatrutide (LY3437943) was developed by Eli Lilly and entered Phase 2 clinical trials (NCT04881760) in 2021–2023 for obesity and type 2 diabetes. The Phase 2 data, published in the New England Journal of Medicine in June 2023, reported mean body-weight reductions of up to 24.2% at 48 weeks in the highest-dose cohort — substantially exceeding the 15–21% reductions reported for tirzepatide and semaglutide in comparable trial settings.

Phase 3 trials (TRIUMPH program) were initiated in mid-2023 and are ongoing as of 2026. The research-grade peptide has become widely available through independent analytical laboratories and third-party-verified suppliers, making it one of the most actively studied research peptides in the metabolic and longevity space.

Lyophilized (freeze-dried) retatrutide powder should be stored at -20°C in a desiccated, light-protected environment for long-term stability (>12 months). Short-term storage (up to 4 weeks) at 2–8°C is acceptable for lyophilized vials awaiting reconstitution.

After reconstitution with bacteriostatic water (0.9% benzyl alcohol), the solution should be kept at 2–8°C and used within 28 days. Do not freeze reconstituted peptide solutions, as ice-crystal formation can denature the tertiary protein structure and significantly reduce bioactivity. Avoid repeated freeze-thaw cycles of the lyophilized powder — aliquot into single-use research vials where possible.